Compare FITBO & BCTXZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Fifth Third Bancorp Depositary Shares each representing a 1/1000th ownership interest in a share of Non-Cumulative Perpetual Preferred Stock Series K
| Metric | FITBO | BCTXZ |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | 18676 | 4 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | FITBO | BCTXZ |
|---|---|---|
| Price | $19.44 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.5K | 10.4K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.91 | $0.06 |
| 52 Week High | $22.16 | $1.20 |
| Indicator | FITBO | BCTXZ |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 52.03 |
| Support Level | $19.20 | $0.12 |
| Resistance Level | $19.80 | $0.17 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 75.73 | 92.31 |
Fifth Third Bancorp is a midsize regional bank in the US, with total assets of over $210 billion as of December 2025. The bank is set to close its acquisition of Comercia on Feb. 1, 2026. Headquartered in Cincinnati, Ohio, Fifth Third has a strong presence in the US Midwest and is currently expanding in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and Treasury management, wealth and asset management, and capital markets.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.